Given the strong anti-tumor efficacy of CD19 CAR-T cells in REH cells, we hypothesized that a more challenging model would be suitable for evaluating the effects of JAK2 inhibitors on CD19 CAR-T cells. The gene discussed is JAK2; the disease is neoplasm.